Image of Ryan Curiel

Ryan Curiel

IP Litigation Attorney

Email

ryan.curiel@aoshearman.com

Phone

+1 212 756 1172

Offices

New York

V-CARD
Ryan Curiel is an IP Litigation Attorney in the Intellectual Property practice in New York. He has experience working on complex patent litigations and due diligence projects, involving small molecule and biologic pharmaceuticals, and medical devices.

Ryan graduated from the Massachusetts Institute of Technology (MIT) with a Bachelor of Science in Biology, and a minor in Chemistry. While at MIT, he interned at Los Alamos National Laboratory working on the Human Genome Project. After MIT, he researched and performed clinical exams in the Neurovascular Laboratory of the Department of Neuroradiology at Massachusetts General Hospital in Boston. Prior to law school, he worked in drug discovery for both small and large, biotechnology and pharmaceutical companies in Cambridge and Boston, Massachusetts. During law school, Ryan was a legal intern at Jazz at Lincoln Center and two boutique IP law firms.

Ryan has been with the firm since 2022 and became a registered patent practitioner in 2024.

Experience

Pro bono

  • Successfully argued on behalf a client who was incarcerated for over 41 years at their modification of sentence hearing, which resulted in their sentence of life plus 35 years being modified to time served and their release into a reentry program later that evening.

Published Work

  • US of Neurovascular Occlusive Disease: Interpretive Pearls and Pitfalls, Radiographics, 2002 Sep-Oct; 22(5):1165-76.

Qualifications

Admissions

Admitted: Bar of the State of New York, 2011

U.S. Patent and Trademark Office (USPTO), 2023

Academic

JD, Northeastern University School of Law, 2007

SB, Biology, Massachusetts Institute of Technology, 1999

Disclaimer
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.